Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Langleben, Adrian
  • Supko, Jeffrey G
  • Hotte, Sebastien
  • Lorusso, Patricia
  • Miller, Wilson H
  • Hurtubise, Annie
  • Leggett, David S
  • Li, Wei
  • Borodyanski, Laura
  • Li, Chiang J

publication date

  • April 15, 2010